Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study.
Rovida F, Cassaniti I, Percivalle E, Sarasini A, Paolucci S, Klersy C, Cutti S, Novelli V, Marena C, Luzzaro F, De Vito G, Schiavo R, Lo Cascio G, Lilleri D, Baldanti F. Rovida F, et al. Among authors: schiavo r. Int J Infect Dis. 2021 Aug;109:199-202. doi: 10.1016/j.ijid.2021.07.003. Epub 2021 Jul 7. Int J Infect Dis. 2021. PMID: 34242763 Free PMC article.
Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?
Piralla A, Ricchi M, Cusi MG, Prati P, Vicari N, Scarsi G, Gandolfo C, Anichini G, Terrosi C, Percivalle E, Vecchio Nepita E, Bergami F, Tallarita M, Di Martino R, Ferrari A, Rovida F, Lunghi G, Schiavo R, Baldanti F. Piralla A, et al. Among authors: schiavo r. Int J Infect Dis. 2021 Jan;102:299-302. doi: 10.1016/j.ijid.2020.10.072. Epub 2020 Oct 30. Int J Infect Dis. 2021. PMID: 33130202 Free PMC article.
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Lasagna A, Agustoni F, Percivalle E, Borgetto S, Paulet A, Comolli G, Sarasini A, Bergami F, Sammartino JC, Ferrari A, Zavaglio F, Arena F, Lilleri D, Secondino S, Falzoni M, Schiavo R, Klersy C, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: schiavo r. ESMO Open. 2021 Oct;6(5):100272. doi: 10.1016/j.esmoop.2021.100272. Epub 2021 Sep 1. ESMO Open. 2021. PMID: 34543863 Free PMC article.
COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy.
Cavanna L, Citterio C, Biasini C, Madaro S, Bacchetta N, Lis A, Cremona G, Muroni M, Bernuzzi P, Lo Cascio G, Schiavo R, Mutti M, Tassi M, Mariano M, Trubini S, Bandieramonte G, Maestri R, Mordenti P, Marazzi E, Vallisa D. Cavanna L, et al. Among authors: schiavo r. Eur J Cancer. 2021 Nov;157:441-449. doi: 10.1016/j.ejca.2021.08.035. Epub 2021 Sep 2. Eur J Cancer. 2021. PMID: 34601285 Free PMC article.
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
Lasagna A, Lilleri D, Agustoni F, Percivalle E, Borgetto S, Alessio N, Comolli G, Sarasini A, Bergami F, Sammartino JC, Ferrari A, Zavaglio F, Arena F, Secondino S, Falzoni M, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: schiavo r. ESMO Open. 2022 Feb;7(1):100359. doi: 10.1016/j.esmoop.2021.100359. Epub 2021 Dec 11. ESMO Open. 2022. PMID: 34973510 Free PMC article.
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020.
Lai A, Bergna A, Toppo S, Morganti M, Menzo S, Ghisetti V, Bruzzone B, Codeluppi M, Fiore V, Rullo EV, Antonelli G, Sarmati L, Brindicci G, Callegaro A, Sagnelli C, Francisci D, Vicenti I, Miola A, Tonon G, Cirillo D, Menozzi I, Caucci S, Cerutti F, Orsi A, Schiavo R, Babudieri S, Nunnari G, Mastroianni CM, Andreoni M, Monno L, Guarneri D, Coppola N, Crisanti A, Galli M, Zehender G; SCIRE-SARS-CoV-2 Italian Research Enterprise-Collaborative Group. Lai A, et al. Among authors: schiavo r. Sci Rep. 2022 Apr 6;12(1):5736. doi: 10.1038/s41598-022-09738-0. Sci Rep. 2022. PMID: 35388091 Free PMC article.
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Alessio N, Comolli G, Sarasini A, Sammartino JC, Ferrari A, Arena F, Secondino S, Cicognini D, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: schiavo r. ESMO Open. 2022 Apr;7(2):100458. doi: 10.1016/j.esmoop.2022.100458. Epub 2022 Mar 11. ESMO Open. 2022. PMID: 35427842 Free PMC article.
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Comolli G, Sarasini A, Sammartino JC, Ferrari A, Arena F, Cicognini D, Schiavo R, Lo Cascio G, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: schiavo r. Ann Oncol. 2022 Nov;33(11):1207-1208. doi: 10.1016/j.annonc.2022.07.012. Epub 2022 Aug 1. Ann Oncol. 2022. PMID: 35926815 Free PMC article. No abstract available.
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Serra F, Comolli G, Sarasini A, Sammartino JC, Ferrari A, Arena F, Secondino S, Cicognini D, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: schiavo r. ESMO Open. 2022 Oct;7(5):100574. doi: 10.1016/j.esmoop.2022.100574. Epub 2022 Aug 5. ESMO Open. 2022. PMID: 36029652 Free PMC article.
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.
Lasagna A, Cassaniti I, Arena F, Bergami F, Percivalle E, Comolli G, Sarasini A, Ferrari A, Cicognini D, Schiavo R, Lo Cascio G, Pedrazzoli P, Baldanti F. Lasagna A, et al. Among authors: schiavo r. Int J Mol Sci. 2023 Apr 4;24(7):6731. doi: 10.3390/ijms24076731. Int J Mol Sci. 2023. PMID: 37047704 Free PMC article.
97 results